ACAD ACADIA PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1070494 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.8%
TTM net income YoY38.7%
TTM EPS YoY36.8%
Revenue 3-yr CAGR23.9%
Net income 3-yr CAGR—
Margins
Gross margin90.5%
Operating margin10.2%
Net margin30.1%
FCF margin6.8%
EBITDA margin10.3%
Returns
ROE31.4%
ROA23.2%
ROIC (approx.)14.2%
Asset turnover0.77x
Leverage & solvency
Liabilities / assets22.7%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.27x
Accruals ratio16.9%
Payout ratio—
Capex / revenue1.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $342.29M | $307.96M | $268.06M | $283.99M | $278.63M | $264.57M | $244.32M | $259.60M |
| Cost of revenue | $35.09M | $28.32M | $24.79M | $26.23M | $21.65M | $20.73M | $20.39M | $21.80M |
| Gross profit | $307.20M | $279.64M | $243.27M | $257.76M | $256.99M | $243.83M | $223.93M | $237.80M |
| R&D expense | $76.28M | $81.56M | $76.87M | $84.76M | $87.83M | $77.95M | $78.27M | $100.73M |
| SG&A expense | $159.20M | $160.25M | $171.02M | $155.62M | $133.40M | $133.51M | $126.37M | $130.08M |
| Operating income | $71.72M | $37.84M | -$4.62M | $17.39M | $35.76M | $32.37M | $19.29M | $153.50M |
| Pretax income | $80.44M | $46.47M | $3.98M | $26.32M | $44.59M | $40.21M | $27.78M | $161.09M |
| Income tax | $26.91M | $14.97M | $344,000 | -$247.25M | -$27.18M | $13.54M | $8.79M | $17.34M |
| Net income | $53.52M | $31.50M | $3.64M | $273.57M | $71.78M | $26.67M | $18.99M | $143.74M |
| EBITDA | $72.41M | $38.27M | -$4.34M | $17.59M | $35.98M | $32.59M | $19.52M | $153.73M |
| EPS (basic) | 0.31 | 0.18 | 0.02 | — | 0.43 | 0.16 | 0.11 | — |
| EPS (diluted) | 0.31 | 0.18 | 0.02 | — | 0.42 | 0.16 | 0.11 | — |
| Weighted avg. shares (diluted) | 175.47M | 172.85M | 172.71M | — | 170.65M | 168.68M | 167.67M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $322.37M | $384.99M | $282.21M | $177.69M | $258.00M | $253.64M | $217.70M | $319.59M |
| Short-term investments | $654.08M | $571.49M | $569.25M | $641.99M | $589.02M | $508.36M | $463.88M | $436.40M |
| Receivables | $161.02M | $150.64M | $135.35M | $121.46M | $115.85M | $107.50M | $105.74M | $98.74M |
| Inventory | $106.84M | $108.67M | $112.29M | $111.37M | $105.98M | $110.53M | $102.97M | $91.69M |
| Current assets | $1.27B | $1.22B | $1.10B | $1.06B | $1.08B | $960.55M | $870.94M | $938.32M |
| PP&E, net | $18.40M | $17.11M | $14.65M | $7.51M | $3.71M | $3.55M | $3.50M | $4.21M |
| Intangibles | $135.48M | $103.45M | $106.17M | $108.89M | $111.61M | $114.34M | $117.06M | $119.78M |
| Total assets | $1.79B | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B |
| Current liabilities | $332.22M | $361.44M | $305.52M | $277.11M | $356.58M | $330.02M | $302.53M | $394.87M |
| Total liabilities | $406.66M | $436.29M | $357.16M | $336.81M | $413.50M | $403.17M | $367.13M | $454.96M |
| Shareholders' equity | $1.39B | $1.31B | $1.25B | $1.23B | $917.27M | $822.38M | $765.24M | $732.79M |
| Shares outstanding | 172.79M | 172.13M | 171.09M | 170.31M | 169.15M | 168.61M | 167.12M | 166.71M |
| Cash flow statement | ||||||||
| Operating cash flow | $11.50M | $100.78M | $33.98M | -$48.73M | $74.29M | $63.96M | $20.32M | $40.38M |
| Capital expenditure | $1.24M | $5.09M | $5.21M | $4.00M | $388,000 | $297,000 | $0 | $453,000 |
| Free cash flow | $10.26M | $95.69M | $28.77M | -$52.74M | $73.90M | $63.66M | $20.32M | $39.93M |
| Investing cash flow | -$86.15M | -$8.53M | $66.28M | -$55.87M | -$79.35M | -$43.29M | -$124.05M | $122.15M |
| Financing cash flow | $11.87M | $10.49M | $4.23M | $22.67M | $9.42M | $15.96M | $1.84M | $1.97M |
| Depreciation & amortization | $688,000 | $434,000 | $271,000 | $202,000 | $227,000 | $213,000 | $229,000 | $226,000 |
| Stock-based compensation | $17.45M | $16.94M | $14.70M | $13.23M | $13.18M | $14.34M | $11.38M | $10.45M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.